Search

everythinglearnresearchcommunity

for

Search:↓

A user on dutasteride for hair loss noticed hair regrowth on their head but a significant reduction in body hair growth. They plan to switch to finasteride and dutasteride and are considering testosterone replacement therapy but are concerned about its effects on hair growth.

User shares 2-month progress with fin, min, dermarolling. Others discuss consistency, regrowth, shedding, and potential side effects.

Treatments for hair loss, such as Minoxidil, Finasteride and RU58841. The first user asked for proof of the effectiveness of these treatments, and the second user responded with a humorous reply.

Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hair loss, while castor oil is recommended to strengthen hair roots and reduce shedding.

The conversation is about a 21-year-old seeking advice on managing hair loss, considering options like shaving, hair implants, or using treatments like finasteride and minoxidil. The user is concerned about self-image and the social implications of being bald at a young age.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

The conversation discusses the safety and use of ketoconazole shampoo for hair loss, with mentions of zinc pyrithione and selenium sulfide. Users debate the safety of these ingredients, particularly zinc pyrithione, and share opinions on regulatory differences between Europe and the US.

The conversation discusses switching from oral finasteride to topical RU58841 for hair loss, with concerns about hormonal effects and libido. Some users suggest alternatives like dutasteride, while others share mixed experiences with RU58841's effectiveness.

The user shared progress pictures after 7 months of using 3.5 mg of minoxidil and finasteride orally, reporting significant hair regrowth. They noted the need to continue the treatment indefinitely to maintain results, with no side effects experienced.

The user has experienced significant hair regrowth over 2 years and 3 months using 0.5mg dutasteride and 5mg oral minoxidil, with noticeable improvement in the temples and crown. The user is considering a hair transplant but is encouraged by others to continue with the current treatment due to the impressive results.

A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

A user shared their positive experience with a hair transplant at Moart Clinic, involving approximately 10,000 grafts for a new hairline and crown. The procedure was smooth, with no pain, and the user is very satisfied with the results.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Young individuals experiencing hair loss are discussing their experiences with treatments like minoxidil and finasteride. Some report positive results with finasteride, despite side effects, while others share tips for managing minoxidil-related dandruff.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The user achieved significant hair regrowth using 0.5mg oral Dutasteride, 2.5mg oral Minoxidil, topical Minoxidil twice daily, Ketoconazole shampoo twice a week, and weekly dermastamping with no side effects. Results were noticeable after 2-3 months, with the best results at 9 months.

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

The user shared progress pictures after using topical minoxidil for 8 months and topical finasteride for 5 months, along with other treatments like tretinoin cream, microneedling, and specialized shampoos. They are seeking feedback on their hair regrowth progress and are concerned about reaching a plateau.

Oral minoxidil is gaining popularity due to increased awareness and convenience, despite potential side effects like cardiac issues and unwanted hair growth. Users report mixed results, with some seeing significant regrowth and others experiencing side effects or minimal improvement.

The hair transplant has a straight, unnatural-looking hairline that many find unappealing. The person is not using finasteride or minoxidil, which may affect future hair retention.

Hair cloning for hair loss is unlikely to be available or affordable in the next 10 years. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options, with skepticism about new advancements.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.